PRISM, RDoC, and neuropsychiatric diseases – Interview with Dr Bruce Cuthbert

Dr Cuthbert recently spoke to ECNP press officer Tom Parkhill about RDoC, PRISM, and the future of research into the causes and treatment of mental health issues.

Click here to read the full interview.

6th SC meeting

Mainz, Germany

The sixth PRISM² SC meeting will be held from 01 – 02 November 2023.

3rd GA General Assembly and 5th Steering committee meeting

Madrid, Spain

The third PRISM² General Assembly and fifth Steering Commitee Meeting were held from 23 – 24 May 2023.

4th SC and IMI EU Midterm Review meeting

Amsterdam, The Netherlands

The fourth PRISM² SC and IMI EU Midterm Review meeting were held from 09 – 10 February 2023.

Pointing the way to a more precise psychiatry – Interview with Dr Hugh Marston

Dr Hugh Marston, head of Global CNS Diseases at Boehringer Ingelheim (BI), is the industry lead on the PRISM project. He discusses the industry perspective with ECNP Press Officer, Tom Parkhill.

Click here to read the full interview.

2nd General Assembly and 3rd Steering Committee meeting

Mainz, Germany

The second PRISM² General Assembly and third Steering Committee Meeting were held from 09 – 10 June 2022.

We were very happy about holding our first f2f meeting and were looking forward to see as many consortium members as possible there in person.

More information will follow soon. Check your email inbox!

1. Newsletter December 2021

PRISM² Closing in on Biomarkers. Click here to read more.

Interview with Professor Martien Kas

Professor Martien Kas is interviewed by Tom Parkhill (ECNP). Professor Kas is the PRISM academic project coordinator and Professor of Behavioural Neuroscience at the University of Groningen.

The interview gives some background information on PRISM and explains the goals for PRISM 2. Click here to read the full interview.

PRISM 2 begins today!

The PRISM 2 project starts today, on the 1st of April 2021. Based on the fantastic outcome, implantation, and impact of PRISM results, we received funding for 3 years to extend our research efforts into Major Depressive Disorder (MDD), explore the causality between the quantitative variation in default mode network (DMN) integrity and social dysfunction, and to intensify communication with various stakeholders.